Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 1995;77:54-63

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mueller, H. W.
Right arrow Articles by Willerson, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mueller, H. W.
Right arrow Articles by Willerson, J. T.
(Circulation Research. 1995;77:54-63.)
© 1995 American Heart Association, Inc.


Articles

Measurement of Platelet-Activating Factor in a Canine Model of Coronary Thrombosis and in Endarterectomy Samples From Patients With Advanced Coronary Artery Disease

Howard W. Mueller, Courtney A. Haught, Janice M. McNatt, Kexin Cui, Simon J. Gaskell, Dennis A. Johnston, James T. Willerson

From the Division of Cardiology (H.W.M., C.A.H., J.M.M., K.C., J.T.W.), University of Texas Health Science Center, Houston; the Center for Experimental Therapeutics (S.J.G.), Baylor College of Medicine, Houston, Tex; and the Department of Biomathematics (D.A.J.), M.D. Anderson Cancer Center, Houston, Tex.

Correspondence to Dr Howard W. Mueller, Division of Cardiology, University of Texas Health Science Center, 6431 Fannin St, Houston, TX 77030.

Abstract Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a potent phospholipid mediator of numerous inflammatory and thrombotic responses. The purpose of this study was to determine if PAF synthesis is elevated in damaged coronary arteries after a sustained period of cyclic flow variation (CFV), a phenomenon caused by alternating periods of thrombosis and reperfusion at sites of endothelial injury. Cyclic flow was established and maintained in the left anterior descending coronary arteries (LADs) of 10 dogs. After 8 hours of CFV, the section of damaged LAD containing the thrombus and control sections of the circumflex artery, carotid artery, and saphenous vein was excised, and the total lipids were extracted. The PAF was then purified by silica column chromatography and high-performance liquid chromatography and assayed by both a rabbit platelet bioassay and a PAF radioimmunoassay. With the platelet bioassay, PAF levels of 8.9±4.0 (range, 4.8 to 15.5) pg/mg wet wt were found in the damaged LADs from the 10 dogs. This PAF bioactivity was completely inhibited by a PAF receptor antagonist. When the radioimmunoassay was used, slightly higher PAF levels of 16.3±12.9 (range, 4.5 to 41.8) pg/mg wet wt were observed in the LADs. Overall, these PAF levels were 3- to 64-fold higher than in the control vessels when either assay method was used. Although increases in PAF were observed in the damaged LADs, measurements of PAF in blood samples taken from the LAD and the aorta (control) failed to demonstrate any site-specific increase of PAF in the blood. In related experiments, PAF was also measured in 23 endarterectomy samples taken from the coronary arteries of 16 patients with severe atherosclerosis. The PAF levels in these samples were highly variable (2.9±2.2 [range, 0.3 to 8.5] pg/mg wet wt) and showed no correlation with tissue mass, suggesting that PAF is affected by factors other than the simple presence of atherosclerotic tissue in the vessel. These findings provide direct evidence that PAF is synthesized locally at the site of endothelial injury during thrombosis and that PAF accumulates in the atherosclerotic plaque of some patients with advanced coronary artery disease.


Key Words: platelet-activating factor • coronary thrombosis • cyclic flow variations • unstable angina • atherosclerosis




This article has been cited by other articles:


Home page
ICVTSHome page
D. Nezic, A. Knezevic, S. Micovic, and M. Cirkovic
eComment: Islets technique to reduce endarterectomized area included into graft during left anterior descending coronary artery endarterectomy
Interactive CardioVascular and Thoracic Surgery, June 1, 2009; 8(6): 665 - 665.
[Full Text] [PDF]


Home page
J. Lipid Res.Home page
D. C. Tsoukatos, I. Brocheriou, V. Moussis, C. P. Panopoulou, E. D. Christofidou, S. Koussissis, S. Sismanidis, E. Ninio, and S. Siminelakis
Platelet-activating factor acetylhydrolase and transacetylase activities in human aorta and mammary artery
J. Lipid Res., October 1, 2008; 49(10): 2240 - 2249.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
D. G. Nezic, A. M. Knezevic, Z. D. Antonic, and M. Dj. Jovic
Repair of Separated Coronary Segments Resulting From a Complicated Coronary Endarterectomy
Ann. Thorac. Surg., November 1, 2007; 84(5): 1768 - 1770.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Arakawa, J.-Y. Qian, D. Baatar, K. Karasawa, Y. Asada, Y. Sasaguri, E. R. Miller, J. L. Witztum, and H. Ueno
Local Expression of Platelet-Activating Factor-Acetylhydrolase Reduces Accumulation of Oxidized Lipoproteins and Inhibits Inflammation, Shear Stress-Induced Thrombosis, and Neointima Formation in Balloon-Injured Carotid Arteries in Nonhyperlipidemic Rabbits
Circulation, June 21, 2005; 111(24): 3302 - 3309.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
P. Turunen, J. Jalkanen, T. Heikura, H. Puhakka, J. Karppi, K. Nyyssonen, and S. Yla-Herttuala
Adenovirus-mediated gene transfer of Lp-PLA2 reduces LDL degradation and foam cell formation in vitro
J. Lipid Res., September 1, 2004; 45(9): 1633 - 1639.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
V. Stangl, G. Baumann, K. Stangl, and S. B Felix
Negative inotropic mediators released from the heart after myocardial ischaemia-reperfusion
Cardiovasc Res, January 1, 2002; 53(1): 12 - 30.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. A. Ruel, F. Wang, M. E. Bourke, J.-Y. Dupuis, J. A. Robblee, W. J. Keon, and F. D. Rubens
Is tranexamic acid safe in patients undergoing coronary endarterectomy?
Ann. Thorac. Surg., May 1, 2001; 71(5): 1508 - 1511.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
I. Brocheriou, D. Stengel, L. Mattsson-Hulten, J. Stankova, M. Rola-Pleszczynski, F. Koskas, O. Wiklund, Y. Le Charpentier, and E. Ninio
Expression of Platelet-Activating Factor Receptor in Human Carotid Atherosclerotic Plaques : Relevance to Progression of Atherosclerosis
Circulation, November 21, 2000; 102(21): 2569 - 2575.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
G. Montrucchio, G. Alloatti, and G. Camussi
Role of Platelet-Activating Factor in Cardiovascular Pathophysiology
Physiol Rev, October 1, 2000; 80(4): 1669 - 1699.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. W. Kinn and R. J. Bache
Effect of Platelet Activation on Coronary Collateral Blood Flow
Circulation, October 6, 1998; 98(14): 1431 - 1437.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. C. Tsoukatos, M. Arborati, T. Liapikos, K. L. Clay, R. C. Murphy, M. J. Chapman, and E. Ninio
Copper-Catalyzed Oxidation Mediates PAF Formation in Human LDL Subspecies : Protective Role of PAF:Acetylhydrolase in Dense LDL
Arterioscler Thromb Vasc Biol, December 1, 1997; 17(12): 3505 - 3512.
[Abstract] [Full Text]